What's in UMN Pharma Inc.'s pipeline?

UMN Pharma Inc. has 4 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with UMN Pharma Inc.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Takeda.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/umn-pharma-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

UMN Pharma Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

UMN Pharma Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
approved egg-derived TIV	approved egg-derived TIV	phase 3
ASP7374	ASP7374	phase 3	TYK2 inhibitor	TYK2 (tyrosine kinase 2)	Immunology

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 1 shared drug class
Takeda · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for UMN Pharma Inc.:

Cite this brief

Drug Landscape (2026). UMN Pharma Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/umn-pharma-inc. Accessed 2026-06-10.